XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES (Details)
$ in Thousands
Dec. 10, 2015
USD ($)
Jun. 10, 2015
USD ($)
product
Dec. 20, 2022
licenseAgreement
Loss Contingencies [Line Items]      
Number of license agreements terminated | licenseAgreement     2
Agensys, Inc. | Licensing Agreements      
Loss Contingencies [Line Items]      
Nonrefundable upfront fee $ 3,000    
Milestone payments upon first achievement of specified clinical milestones 5,000    
Milestone payments upon achievement of specified clinical milestones for each licensed product 50,000    
Milestone payments upon achievement of sales milestones 75,000    
Option exercise fee 5,000    
Milestone payments reduced upon exercise of option $ 65,000    
Termination period, number of years after first commercial sale of licensed product 10 years    
Termination period, notice of failure on uncured items 60 days    
Period of notice of failure on uncured items, if material breach is related to failure to make payments 30 days    
BioVec Pharma Inc | Licensing Agreements      
Loss Contingencies [Line Items]      
Nonrefundable upfront fee   $ 100  
Milestone payments upon first achievement of specified clinical milestones   $ 250  
Termination period, notice of failure on uncured items   60 days  
Upfront fee payment period, number of days from effective date   10 days  
License costs due upon first release of product   $ 300  
License costs due upon first release of product, period of payment   10 days  
License maintenance fee earned during period   $ 150  
License agreement, annual fee period, from first IND filing   30 days  
Milestone payments, number of initial products | product   3  
License agreement, milestone payments upon receipt of FDA or EMA registration   $ 2,000  
Termination notice period for any other breach   90 days  
Termination period, after insolvency event   30 days